iRadimed (NASDAQ:IRMD) Share Price Passes Above 50-Day Moving Average – Here’s Why

iRadimed Corporation (NASDAQ:IRMD) shares crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $100.44 and traded as high as $102.91. iRadimed shares last traded at $102.80, with a volume of 69,742 shares.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Roth Mkm reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Stock Up 0.2%

The business’s 50 day moving average is $100.46 and its 200 day moving average is $89.30. The company has a market cap of $1.28 billion, a P/E ratio of 57.06 and a beta of 1.12.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.05. The business had revenue of $22.69 million for the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities research analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.8%. This is a boost from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date was Monday, February 23rd. iRadimed’s payout ratio is presently 45.71%.

Insider Buying and Selling

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $100.04, for a total value of $500,200.00. Following the completion of the transaction, the chief executive officer directly owned 2,250,000 shares in the company, valued at approximately $225,090,000. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 40,000 shares of company stock valued at $3,985,100 in the last ninety days. Insiders own 36.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Hsbc Holdings PLC boosted its stake in iRadimed by 19.2% in the fourth quarter. Hsbc Holdings PLC now owns 21,559 shares of the medical equipment provider’s stock valued at $2,103,000 after acquiring an additional 3,468 shares in the last quarter. Aristides Capital LLC increased its position in shares of iRadimed by 5.0% during the fourth quarter. Aristides Capital LLC now owns 27,734 shares of the medical equipment provider’s stock worth $2,698,000 after purchasing an additional 1,309 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after purchasing an additional 205,783 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of iRadimed by 473.9% during the 4th quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after purchasing an additional 29,010 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new stake in shares of iRadimed in the 4th quarter worth $1,679,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.